Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 26 April
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc
26
April 2017, London UK
NOTICE
To the
Holders of
5.375%
Notes due 2034 CUSIP # 377372 AB3
of
GlaxoSmithKline Capital Inc.
NOTICE
IS HEREBY GIVEN, pursuant to Section 8.08 of the Indenture, dated
as of April 6, 2004, as amended and supplemented by the First
Supplemental Indenture dated as of March 18, 2013 and by the Second
Supplemental Indenture dated as of March 21, 2014 (the
"Indenture"), by and among GlaxoSmithKline Capital Inc.,
GlaxoSmithKline plc, as guarantor, and Law Debenture Trust Company
of New York, as Trustee, that Law Debenture Trust Company of New
York has resigned as trustee, registrar, paying agent and
authenticating agent under the Indenture.
Pursuant to Section
8.08 of the Indenture, Deutsche Bank Trust Company Americas, a
banking corporation duly organized and existing under the laws of
New York, has accepted appointment as trustee, registrar, paying
agent and authenticating agent under the Indenture. The address of
the designated corporate trust office of the successor Trustee is
60 Wall Street, 16th Floor, New York, NY 10005.
Law
Debenture Trust Company of New York's resignation as trustee,
registrar and paying agent and Deutsche Bank Trust Company
America's appointment as successor trustee, registrar, paying agent
and authenticating agent were effective as of the opening of
business on April 26, 2017.
Dated:
April 26, 2017
GLAXOSMITHKLINE
CAPITAL INC.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
26, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|